Sugi Predict

Sugi Predict / Targets / UGT2B17

UGT2B17

UDP-glucuronosyltransferase 2B17 · O75795 · UGT2B17 on Sugi Atlas →

1,588 patent compounds predicted against UGT2B17, 181 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6799194 SCHEMBL6799194 1.00 2/20
SCHEMBL1508636 SCHEMBL1508636 0.82 2/20
SCHEMBL10286363 SCHEMBL10286363 0.72 2/20
SCHEMBL22222496 SCHEMBL22222496 0.64 2/20
SCHEMBL703510 SCHEMBL703510 0.62 2/20
SCHEMBL5272877 SCHEMBL5272877 0.62 2/20
SCHEMBL30831935 SCHEMBL30831935 0.62 2/20
SCHEMBL15286569 SCHEMBL15286569 0.62 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1976240) 0.61 2/20
SCHEMBL5173559 SCHEMBL5173559 0.60 2/20
SCHEMBL12014020 SCHEMBL12014020 0.58 2/20
SCHEMBL768366 SCHEMBL768366 0.57 2/20
SCHEMBL15287102 SCHEMBL15287102 0.57 2/20
SCHEMBL15825377 SCHEMBL15825377 0.57 2/20
SCHEMBL27734788 SCHEMBL27734788 0.57 2/20
SCHEMBL412687 SCHEMBL412687 0.56 2/20
SCHEMBL10283629 SCHEMBL10283629 0.56 2/20
SCHEMBL20362246 SCHEMBL20362246 0.56 2/20
SCHEMBL22417595 SCHEMBL22417595 0.56 2/20
SCHEMBL22548686 SCHEMBL22548686 0.56 2/20

Clinical trials — most relevant to UGT2B17 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cholestatic Drug-induced Liver Injury PHASE4UNKNOWN
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians PHASE4UNKNOWN
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy PHASE4COMPLETED
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) PHASE3RECRUITING
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma PHASE1/PHASE2RECRUITING
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors PHASE1/PHASE2UNKNOWN
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma PHASE1/PHASE2RECRUITING
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer PHASE2COMPLETED
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 PHASE2RECRUITING
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors PHASE1UNKNOWN
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood PHASE1COMPLETED
Study of FID-022 in Participants With Advanced Solid Tumors PHASE1RECRUITING
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac EARLY_PHASE1RECRUITING
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD nanUNKNOWN
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C nanCOMPLETED
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer nanCOMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy nanRECRUITING
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a UGT2B17 binder may also engage these)

ProteinNameSimilarity
P54855 — 1.000 P54855 →
O77649 — 1.000 O77649 →
O02663 — 1.000 O02663 →
O97951 — 1.000 O97951 →
P36510 — 1.000 P36510 →
Q6PDD0 — 1.000 Q6PDD0 →
P09875 — 0.999 P09875 →
P19488 — 0.999 P19488 →
Q8BWQ1 — 0.999 Q8BWQ1 →
Q80X89 — 0.999 Q80X89 →
O75310 — 0.999 O75310 →
Q6K1J1 — 0.999 Q6K1J1 →
Q9XT55 — 0.998 Q9XT55 →
P06133 — 0.998 P06133 →
P36512 — 0.998 P36512 →
Q6UWM9 — 0.998 Q6UWM9 →
P17717 — 0.998 P17717 →
Q9GLD9 — 0.997 Q9GLD9 →
Q8WN97 — 0.997 Q8WN97 →
Q9R110 — 0.997 Q9R110 →
O19103 — 0.997 O19103 →
Q9TSL6 — 0.997 Q9TSL6 →
P36537 — 0.996 P36537 →
Q5RFJ3 — 0.996 Q5RFJ3 →
P08542 — 0.996 P08542 →
UGT2B7 UDP-glucuronosyltransferase 2B7 0.996 landscape →
P0DTE5 — 0.995 P0DTE5 →
Q9BY64 — 0.994 Q9BY64 →
P36513 — 0.993 P36513 →
P08541 — 0.993 P08541 →